OREANDA-NEWS. September 04, 2015. Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that it has appointed Westwicke Partners as its investor relations adviser in the U.S. Westwicke Partners provides strategic investor relations and capital markets advisory services exclusively to public and private companies in the healthcare sector.

Graham Lumsden, CEO of Motif, said: "We look forward to building a relationship with the Westwicke team and to leveraging their experience as we continue to move our clinical development programs forward".

About Westwicke Partners

Westwicke Partners provides strategic investor relations and capital markets advisory services exclusively to healthcare companies. With offices in Baltimore, Boston, San Francisco and San Diego, the firm works with over 80 public and private companies across all subsectors of healthcare. Services provided by Westwicke include corporate messaging and positioning, investor presentation review, sell side relationship building, buy side targeting, earnings call preparation, capital markets advisory, pre-IPO planning and execution, and investor day meetings. All of Westwicke's senior professionals have extensive Wall Street experience as former sell side and buy side research analysts, portfolio managers, investment bankers, institutional sales people, and equity capital markets professionals. The firm works with its clients to help position their story properly within the investment community, raise their visibility on Wall Street, and develop value-added strategies to build a quality, long-term shareholder base and enhance equity market value. For additional information about Westwicke please visit www.westwicke.com.